中外医学研究
中外醫學研究
중외의학연구
Chinese and Foreign Medical Research
2015年
29期
24-25,26
,共3页
糖尿病肾病%羟苯磺酸钙%厄贝沙坦%联合治疗
糖尿病腎病%羥苯磺痠鈣%阨貝沙坦%聯閤治療
당뇨병신병%간분광산개%액패사탄%연합치료
Diabetic nephropathy%Calcium dobesilate%Irbesartan%Combination therapy
目的：分析羟苯磺酸钙联合厄贝沙坦治疗早期糖尿病肾病的临床疗效与价值。方法：选取2014年9月-2015年5月笔者所在医院收治的92例早期糖尿病肾病患者作为研究对象，按患者编号分为对照组和观察组，每组各46例。对照组给予患者厄贝沙坦治疗，观察组采用苯磺酸钙联合厄贝沙坦治疗，疗程均为两个月。治疗前后，分别测量两组各项临床指标，并将结果进行对比分析。结果：治疗前后，两组的空腹血糖(FPG)、血肌酐(Scr)、平均动脉压(MAP)及糖化血红蛋白(HbA1c)水平比较，差异均无统计学意义(P>0.05)，且组间比较差异无统计学意义(P>0.05)；两组治疗后24 h尿白蛋白排泄率(UAER)水平较治疗前均显著下降(P<0.05)，且观察组下降幅度明显大于对照组(P<0.05)；对照组与观察组的总有效率分别是39.13%、80.43%，观察组的总有效率显著高于对照组(P<0.05)。结论：给予早期糖尿病肾病患者羟苯磺酸钙联合厄贝沙坦治疗，有助于降低尿白蛋白排泄量，有效提高治疗效果，值得临床大力推广。
目的：分析羥苯磺痠鈣聯閤阨貝沙坦治療早期糖尿病腎病的臨床療效與價值。方法：選取2014年9月-2015年5月筆者所在醫院收治的92例早期糖尿病腎病患者作為研究對象，按患者編號分為對照組和觀察組，每組各46例。對照組給予患者阨貝沙坦治療，觀察組採用苯磺痠鈣聯閤阨貝沙坦治療，療程均為兩箇月。治療前後，分彆測量兩組各項臨床指標，併將結果進行對比分析。結果：治療前後，兩組的空腹血糖(FPG)、血肌酐(Scr)、平均動脈壓(MAP)及糖化血紅蛋白(HbA1c)水平比較，差異均無統計學意義(P>0.05)，且組間比較差異無統計學意義(P>0.05)；兩組治療後24 h尿白蛋白排洩率(UAER)水平較治療前均顯著下降(P<0.05)，且觀察組下降幅度明顯大于對照組(P<0.05)；對照組與觀察組的總有效率分彆是39.13%、80.43%，觀察組的總有效率顯著高于對照組(P<0.05)。結論：給予早期糖尿病腎病患者羥苯磺痠鈣聯閤阨貝沙坦治療，有助于降低尿白蛋白排洩量，有效提高治療效果，值得臨床大力推廣。
목적：분석간분광산개연합액패사탄치료조기당뇨병신병적림상료효여개치。방법：선취2014년9월-2015년5월필자소재의원수치적92례조기당뇨병신병환자작위연구대상，안환자편호분위대조조화관찰조，매조각46례。대조조급여환자액패사탄치료，관찰조채용분광산개연합액패사탄치료，료정균위량개월。치료전후，분별측량량조각항림상지표，병장결과진행대비분석。결과：치료전후，량조적공복혈당(FPG)、혈기항(Scr)、평균동맥압(MAP)급당화혈홍단백(HbA1c)수평비교，차이균무통계학의의(P>0.05)，차조간비교차이무통계학의의(P>0.05)；량조치료후24 h뇨백단백배설솔(UAER)수평교치료전균현저하강(P<0.05)，차관찰조하강폭도명현대우대조조(P<0.05)；대조조여관찰조적총유효솔분별시39.13%、80.43%，관찰조적총유효솔현저고우대조조(P<0.05)。결론：급여조기당뇨병신병환자간분광산개연합액패사탄치료，유조우강저뇨백단백배설량，유효제고치료효과，치득림상대력추엄。
Objective:To analyze the clinical curative effect and value of the calcium dobesilate combined with irbesartan in treatment of early diabetic nephropathy.Method: According to the patient number,92 patients with early diabetic nephropathy in our hospital from September 2014 to May 2015 were divided into the control group and the observation group,46 cases in each group.The control group was received Irbesartan treatment,the observation group was received calcium irbesartan treatment.Treatment with a course of two months.Before and after treatment, the clinical parameters were measured, and the results were analyzed of the two groups.Result: Before and after treatment,the fasting plasma glucose(FPG),serum creatinine (Scr),mean arterial pressure(MAP) and glycosylated hemoglobin(HbA1c) levels of the two groups,which had no significant change(P>0.05), and there was no significant difference between the two groups(P>0.05);after treatment,24 h urinary albumin excretion rate (UAER) levels of the two groups were significantly lower than before treatment(P<0.05),and the observation group decreased more significantly than the control group(P<0.05); the total effective rate of the control group and the observation group were 39.13% and 80.43%, the observation group was better than the control group, there was statistical differences significance(P<0.05).Conclusion:Give calcium dobesilate and irbesartan in treatment of the patiens with early diabetic nephropathy,which helps to reduce the urinary albumin excretion, and effectively improve the therapeutic effect,it is worthy of promotion.
